SAN FRANCISCO — The U.S. Court of Appeals for the Federal Circuit issued an injunction on Tuesday blocking Sandoz Inc. from selling a biosimilar version of Amgen Inc,’s drug Neupogen until the court resolves a pending appeal over the medication’s release.
The drug, which gained U.S. Food and Drug Administration approval in March, would be the first biosimilar to be sold in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
